The cost of publication in Journal of Biomedical Science is borne by the National Science Council, Taiwan.
Research
Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice
-
* Corresponding authors: Shinn-Zong Lin szlin@mail.cmuh.org.tw - Chyou-Wei Wei wcwnina@gate.sinica.edu.tw
- † Equal contributors
1 Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan
2 Department of Emergency Medicine, Tzu Chi General Hospital, Hualien, Taiwan
3 Department of Pathology, China Medical University Hospital, Taichung, Taiwan
4 Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical University and Hospital, Taichung, Taiwan
5 Department of Biotechnology, Asia University, Taichung, Taiwan
6 Institute of Biomedical Nutrition, College of Medicine & Nursing, Hung Kuang University, Sha Lu, Taichung, Taiwan
7 Department of Neurosurgery, China Medical University Hospital, Taichung, Taiwan
Journal of Biomedical Science 2009, 16:47 doi:10.1186/1423-0127-16-47
Published: 7 May 2009Abstract
Human interleukin-15 (hIL15) has anti-tumor activities, but it is not convenient for tumor treatment because of its short half-life. A gene therapy for mouse lung cancer using an adenovirus vector expressing IL15 has been reported. However, adenovirus vector-mediated gene therapy can provoke cellular toxicity and inflammatory reactions. The recombinant adenovirus-associated vector 2 (rAAV2) is safer due to minimal cellular toxicity and immune response. In order to demonstrate that gene therapy can be used safely and successfully for human cancer treatment, the rAAV2 expressing hIL15 gene (rAAV2-hIL15) is applied for human cervical cancer, HeLa cell, in this study. This study successfully demonstrates that rAAV2-hIL15 can express IL15 with bioactivities in vitro and in vivo. In conclusion, our studies show that human cervical cancers are inhibited on animal model with rAAV2-hIL15 treatment and provide a safer and important reference for human cancer gene therapy.